Eos SENOLYTIX Presents Late-Life Survival and Healthspan Data for Mitochondria-Targeted Geropeptide PTC-2105 at the 17th World Congress on Targeting Mitochondria, and Launches “Team Speedy” to Let the Public Follow Its Longest-Lived Mouse
Eos SENOLYTIX, the private biotech merging into PULM, presented late-breaking preclinical data showing once-weekly PTC-2105 significantly extended overall survival in naturally aged mice (log-rank p = 0.0142) versus saline. A PTC-2105-treated mouse nicknamed Speedy is now 167 weeks old, outliving all untreated controls and the ~155-week strain lifespan ceiling, and the company launched a 'Team Speedy' public webpage to track him. Eos also flagged a potentially concerning signal that semaglutide-treated mice entered accelerated terminal decline, and is running a 180-mouse study to confirm; a Phase 1b sarcopenia trial in humans is planned.
Key figures
- Drug Name
- PTC-2105
- Phase Of Trial
- Phase 1b (planned)
- Glp1 comparison
- weight loss with PTC-2105 exceeded semaglutide after ~30 weeks; lean mass increased from baseline
- Planned phase1b
- 12-week placebo-controlled study in adults 60+ with sarcopenia
- Speedy age weeks
- 167
- Survival log rank p
- 0.0142
- Dose 25mg survival p
- 0.0142
- Cancer specific survival p 2 5mg
- 0.0149
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.